What does Alzamend Neuro do?
Alzamend Neuro, Inc. is a Nasdaq Capital Market-listed, clinical-stage biopharmaceutical company developing treatments for Alzheimer’s disease, bipolar disorder, major depressive disorder and post-traumatic stress disorder. It does not sell an approved product and recorded no revenue in the quarter or nine months ended January 31, 2026. Its value rests on clinical evidence, regulatory progress, intellectual-property rights and financing.
The business is concentrated in two licensed candidates. Its official pipeline describes AL001, an ionic cocrystal combining lithium, L-proline and salicylate, and ALZN002, a cell-based vaccine intended to stimulate immunity against beta-amyloid. Both are licensed from the University of South Florida Research Foundation under royalty-bearing worldwide agreements.
Why does this small company matter?
Alzamend is not dominant in neuroscience. Its relevance comes from the strategic problem it is attempting to solve. Conventional lithium remains clinically important in bipolar disorder, but its narrow therapeutic window and systemic toxicity require monitoring and can limit use. AL001 is designed to preserve lithium’s therapeutic mechanism while improving delivery to the brain. ALZN002 pursues a different Alzheimer’s strategy: active immunization rather than repeated passive-antibody dosing. Either concept would need much larger, controlled studies before commercial significance can be established.
| Identity item | Company-specific fact | Research implication |
|---|---|---|
| Business stage | Clinical stage; zero revenue in Q3 FY2026 and the nine months ended January 31, 2026 | Clinical milestones and financing capacity matter more than conventional revenue growth. |
| Core assets | AL001 and ALZN002 | Asset concentration creates meaningful upside from success and severe downside from delay or failure. |
| Operating footprint | Four full-time and two part-time employees at January 31, 2026 | The model depends heavily on external researchers, clinical sites, consultants and contractors. |
| Listing | Nasdaq Capital Market under ALZN | Continued-listing compliance is an operational financing issue, not merely a trading detail. |
How could Alzamend Neuro eventually make money?
The company has no current revenue stream. Economics begin only after successful trials and regulatory approval. Alzamend could commercialize, license rights, partner for development, receive milestones and royalties, or sell an asset. Because the route is not fixed, valuation depends on probability-weighted outcomes rather than a visible sales funnel.
The revenue logic is downstream of four gates
Which candidate carries the larger near-term economic burden?
AL001 and ALZN002 create a two-asset clinical strategy
AL001 is a differentiated-lithium thesis
AL001 combines lithium, proline and salicylate in a patented ionic cocrystal. The hypothesis is that better brain delivery could reduce systemic lithium burden while retaining therapeutic activity. Alzamend believes AL001 may fit the FDA’s Section 505(b)(2) pathway, but its FY2025 Form 10-K warns that qualification is not assured and additional studies may be required.
ALZN002 is an active-immunity Alzheimer’s program
ALZN002 uses mutant-peptide-sensitized dendritic cells to activate T-cells and promote clearance of beta-amyloid. The FDA issued a “study may proceed” letter in October 2022 for a Phase I/IIA trial. The program was later paused after termination of a clinical research organization relationship, and legal costs associated with that dispute became material in FY2026. This makes ALZN002 both an option on a differentiated mechanism and an execution case study in vendor dependence.
| Program | Indications | Stage disclosed in 2026 | Core question |
|---|---|---|---|
| AL001 | Alzheimer’s, bipolar disorder, MDD and PTSD | Phase II program; healthy-subject study reported, bipolar study underway | Can better brain delivery translate into safer, effective long-term treatment? |
| ALZN002 | Alzheimer’s disease | Phase I/IIA program paused in 2024; company expected resumption in 2026 | Can an active cell-based vaccine generate useful immunity with acceptable safety and manufacturability? |
What do Alzamend Neuro’s latest clinical results actually show?
The March 2026 readout strengthened the AL001 delivery hypothesis
In its March 26, 2026 topline announcement, Alzamend reported that AL001 delivered 101% of total lithium blood exposure and 97% of peak blood lithium levels relative to lithium carbonate. Those results fell within the 80%-125% bioequivalence interval cited by the company. It also reported numerically higher lithium concentrations in all 26 measured brain regions, including a roughly 7.8% increase in maximum whole-brain lithium exposure and an earlier brain peak at 6.7 hours versus 8.4 hours.
What are the limitations of the evidence?
The randomized crossover study used six subjects per arm, 14 days of dosing and a 14-day washout. The result is scientifically interesting but too small to establish efficacy, long-term safety or commercial differentiation. Alzamend said the five-study program would total 30 patients and expected bipolar-disorder topline data in Q3 2026, subject to funding.
What does the latest reported financial period show?
The latest full financial package is the Form 10-Q for the quarter ended January 31, 2026. It shows a pre-revenue company increasing clinical activity while relying on financing to offset cash burn. Quarterly R&D spending rose to $1.279 million from $447,000 a year earlier, largely because clinical-trial fees reached $1.016 million. G&A expense rose to $919,000, including $337,000 of professional fees and $310,000 of salaries and benefits.
| Metric | Q3 FY2026 | Q3 FY2025 | Interpretation |
|---|---|---|---|
| Revenue | $0 | $0 | No commercial product or recurring operating revenue. |
| R&D expense | $1.279M | $0.447M | The trial program moved from setup toward active execution. |
| G&A expense | $0.919M | $0.590M | Legal and professional fees increased materially. |
| Net loss | $2.199M | $1.039M | Higher clinical and legal spending more than doubled the quarterly loss. |
| Diluted loss per share | $0.58 | $1.75 | Per-share comparison is distorted by the much larger share count. |
How financially resilient is Alzamend Neuro?
Liquidity is the binding constraint
At January 31, 2026, cash was $2.713 million, current assets were $3.699 million and accounts payable plus accrued liabilities were $1.857 million. Working capital was approximately $1.842 million, insufficient for a multi-trial biotechnology program. Nine-month operating cash use was $5.271 million versus $4.035 million supplied by financing. Management disclosed substantial doubt about continuing as a going concern.
| Balance-sheet item | January 31, 2026 | April 30, 2025 | What changed |
|---|---|---|---|
| Cash | $2.713M | $3.949M | Declined by $1.236M over nine months. |
| Total assets | $4.042M | $4.603M | The asset base remains mostly short-term liquidity rather than productive commercial assets. |
| Accounts payable and accrued liabilities | $1.857M | $0.635M | Obligations increased by $1.223M as trial activity accelerated. |
| Stockholders’ equity | $2.185M | $3.968M | Losses reduced equity below Nasdaq’s $2.5M continued-listing threshold. |
| Accumulated deficit | $64.438M | $58.535M | The deficit increased by the $5.902M nine-month net loss. |
Capital allocation is mostly trial funding and corporate survival
After quarter-end, the company entered a new at-the-market agreement permitting sales of up to $3.0 million of common stock, as described in its March 2026 Form 8-K. Such access can extend operations, but it also makes dilution a recurring part of the investment case. Common shares outstanding increased from 778,733 at April 30, 2025 to 3,804,741 at January 31, 2026, largely through preferred-stock conversions.
Which turning points still shape Alzamend Neuro’s strategy?
Alzamend’s history is a sequence of licensing, financing and clinical-validation events that changed its controlled rights, supporting evidence and funding needs.
-
2016The company was organized and began building its portfolio around University of South Florida Research Foundation technology, establishing the licensed-asset model that still defines the business.
-
2018-2020Additional exclusive licenses broadened AL001 beyond Alzheimer’s into psychiatric indications, increasing the addressable clinical program but also the number of trials requiring capital.
-
2021Alzamend completed its Nasdaq initial public offering at $5.00 per share before later reverse-split adjustments, creating a public-equity funding channel for development.
-
2022-2023AL001 advanced through Phase I and Phase IIA work, while the FDA allowed the ALZN002 IND study to proceed. The company shifted from a licensing story toward a clinical-data story.
-
2024ALZN002 was paused after termination of a CRO relationship. The event exposed the operational risk of running complex trials through external parties and later contributed to substantial legal spending.
-
2025The first MGH “Lithium in Brain” clinical study progressed through enrollment, dosing and completion; a bipolar-disorder study was initiated, concentrating the company’s near-term resources on AL001.
-
2026AL001 produced bioequivalence and brain-delivery signals, while the balance sheet fell below Nasdaq’s minimum equity requirement. Scientific progress and financing risk became more tightly linked.
Why does the sequence matter?
Any strategic advantage must come from converting university-originated intellectual property into clinical evidence efficiently, not from scale. Because each indication expands funding needs, program prioritization is as important as scientific breadth.
Who are Alzamend Neuro’s competitors, and what could differentiate it?
Competition comes from approved standards and much larger drug developers
Alzamend’s annual filing identifies large competitors including Biogen, Eisai, Eli Lilly, Pfizer, Merck and Johnson & Johnson. AL001’s immediate benchmark is generic lithium: inexpensive, familiar and supported by decades of use. Better brain delivery must therefore produce a meaningful safety, tolerability or efficacy advantage large enough to justify a premium.
| Competitive set | Their advantage | Alzamend’s required response |
|---|---|---|
| Generic lithium products | Low price, established prescribing, known efficacy in bipolar disorder | Demonstrate clinically meaningful improvement in tolerability, dosing or therapeutic index. |
| Large neuroscience companies | Capital, regulatory teams, manufacturing, payer access and commercial reach | Produce differentiated data that attracts partnership rather than compete on infrastructure. |
| Approved Alzheimer’s antibodies | Regulatory validation of amyloid-targeting approaches | Show that ALZN002’s active-immunity concept can offer practical dosing or cost advantages without unacceptable safety risk. |
| Other early-stage biotechs | Alternative mechanisms and potentially faster trial execution | Maintain focus, protect licenses and avoid delays caused by contractors or capital shortages. |
What could become a genuine competitive advantage?
The strongest potential resource is the AL001 formulation plus its early imaging dataset. If larger studies confirm equivalent blood exposure, higher brain delivery and better tolerability, the asset could address a known limitation of lithium. The MGH collaboration strengthens measurement quality, but this is not yet a moat: licenses impose milestones and royalties, and competitors have far greater capital.
Who owns Alzamend Neuro, and how is it governed?
Economic ownership is dispersed, but related-party influence remains relevant
The 2026 definitive proxy used 3,804,741 shares at the February 25, 2026 record date. Directors and named executives owned 53,241 shares, or 1.39%. Founder and vice chairman Milton C. Ault III owned 45,193 shares, or 1.18%, including affiliated shares and warrants. Insider economics are diluted, but related-entity governance links remain relevant.
| Holder or group | Beneficial shares | Ownership | Why it matters |
|---|---|---|---|
| Milton C. Ault III | 45,193 | 1.18% | Founder influence extends through affiliated entities, warrants and overlapping leadership relationships. |
| Stephan Jackman | 2,995 | Less than 1% | CEO ownership is primarily represented by exercisable options rather than a large common-stock block. |
| David J. Katzoff | 1,726 | Less than 1% | CFO incentives include equity, but economic control is limited. |
| All directors and named executives | 53,241 | 1.39% | One-share-one-vote governance is not controlled by a large insider block. |
Governance is shaped by a small board and overlapping affiliations
Leadership continuity matters because Alzamend had only six employees at January 31, 2026. Related-party history, overlapping Hyperscale Data executives and repeated equity financing require investors to distinguish operational support from conflicts and dilution.
What opportunities, risks and valuation drivers matter most?
The opportunity is asymmetric but milestone-dependent
AL001’s opportunity is to preserve established lithium pharmacology while reducing enough of its tolerability and monitoring burden to change prescribing. A Section 505(b)(2) path could reduce duplicative work, but approval still requires safety and efficacy evidence. ALZN002 adds a separate Alzheimer’s option with lower near-term visibility.
The Nasdaq deficiency filing said an accepted plan could provide until September 16, 2026 to regain compliance. Delisting risk can reduce liquidity and complicate financing.
What should researchers monitor next?
Why is conventional DCF analysis difficult here?
With zero revenue and unknown launch timing, risk-adjusted net present value is more useful than a standard DCF. Model probability of success, sales, timing, development costs, royalties and dilution; avoid a mature terminal value before credible clinical and reimbursement evidence.
| KPI | Current reference point | How to interpret it |
|---|---|---|
| R&D intensity | 58.2% of Q3 FY2026 operating expense | Higher is constructive only when it produces timely, decision-quality data. |
| Operating cash use | $5.271M for 9M FY2026 | Compare with cash, financing capacity and the cost of planned studies. |
| Working capital | Approximately $1.842M at January 31, 2026 | Positive working capital does not eliminate going-concern risk when future trial costs are large. |
| Whole-brain lithium signal | Approximately 7.8% higher maximum exposure | Useful only if replicated and linked to clinical benefit or better tolerability. |
| Common shares outstanding | 3.805M at January 31, 2026 | Per-share valuation must explicitly model future financing and warrant or preferred conversion effects. |
What is the key takeaway from Alzamend Neuro analysis?
Alzamend is a high-risk clinical developer, not an operating pharmaceutical franchise. Its strongest element is AL001’s differentiated-lithium hypothesis, supported by 2026 bioequivalence, brain-delivery and exploratory pharmacodynamic signals. Its weakest element is financial durability: no revenue, $5.271 million of nine-month operating cash use, $2.713 million of cash, dilution, a going-concern warning and a Nasdaq equity deficiency.
The case shows how licensing, regulation, outsourcing and financing interact in biotechnology. The decisive questions are whether patient studies replicate the imaging signal, whether it improves outcomes or tolerability, and whether development can be funded without excessive per-share dilution.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.